Please note Epocrates will no longer provide this CME offering after December 31, 2015. However this free offering will continue to be available directly from RealCME and there will be no interruption to your account, including credits, certificates and new course offerings.

Please directly access your account by clicking RealCME Health Professional and use the same email address to log in to your account that you have used with EpocratesCME. For security purposes, you will be asked to establish a new password.

Tessa Visits: Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes


Tessa Visits: Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes

Topic: Gastroenterology
Relevant Terms: Ulcerative Colitis, IBD, Non-Responsive UC, Refractory UC, Long-term Therapy, Remission
Primary Audience: physicians who manage patients with ulcerative colitis (UC)
Launch Date: 24-Oct-13
Credits: AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the efficacy and safety data for existing, new and emerging treatments for UC
  2. Appropriately select treatments for patients with UC that maximize the opportunity to achieve remission, avoid relapse and minimize complications in accordance with existing guidelines
  3. Implement evidence-based strategies to improve management of therapeutic non-response or refractoriness in UC


    William J. Sandborn, MD - Program Chair 
    Chief, Division of Gastroenterology
    Professor of Medicine
    UC San Diego School of Medicine
    San Diego, CA
    Marla C. Dubinsky, MD
    Director, Pediatric Inflammatory Bowel Disease Program
    Abe and Claire Levine Chair in Pediatric Inflammatory
    Bowel Disease
    Associate Professor of Pediatrics
    Cedars-Sinai Medical Center
    Los Angeles, CA
    David T. Rubin, MD
    Professor of Medicine
    Co-Director, Inflammatory Bowel Disease Center
    Associate Section Chief, Education
    Section of Gastroenterology, Hepatology and Nutrition
    University of Chicago Medicine
    Chicago, Illinois
    Accreditation Statement and Credit Designation
    The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.                                               
    The AGA Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
    How to Receive Credit
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credit(s)™. You must complete the post-test and evaluation in order to receive credit for this activity. 
    All other participants who successfully complete the post-test and evaluation will receive a certificate of completion.
    A statement of credit will be e-mailed to you and will also be available to print from your user history page. 
    Disclosure of Conflicts of Interest
    In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
    Faculty Disclosures
    Dr. Sandborn has received consulting fees from Janssen, Abbott Laboratories (now AbbVie), UCB Pharma, Salix, Shire, Warner Chilcott, Prometheus Laboratories, Santarus, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos, GlaxoSmithKline, and Millennium (a Takeda company).
    Dr. Sandborn also serves on the Speakers Bureau for AbbVie, and has received research grants from Janssen, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos and GlaxoSmithKline.
    Dr. Dubinsky has served as a consultant for Janssen, Pfizer, Bristol-Myers Squibb, UCB, Abbott, Shire, Prometheus, and Takeda, and has received a research grant from Janssen.
    Dr. Rubin serves as a consultant for Prometheus Pharmaceuticals, AbbVie (Abbott Immunology), UCB Pharma, Centocor/Janssen, Elan Pharmaceuticals, Takeda-Millennium, Given Imaging, Bristol-Meyers Squibb, Ironwood, Lifecore Biomedical, LLC, Emmi, Telsar Pharmaceuticals, Vertex Pharmaceuticals, and Santarus.
    Dr. Rubin has also received grants or research support from Warner Chilcott, Prometheus Pharmaceuticals, AbbVie (Abbott Immunology) (Registry), Shire, and Elan Pharmaceuticals (Registry).
    Additionally, Dr. Rubin is co-founder of Cornerstones Health, Inc., a non-profit medical education entity.
    RMEI Disclosures
    Program planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose. 
    Cynthia M. Kunzer, CMP, has no affiliations with commercial interests to disclose.

    AGA Planning Committee
    AGA Staff and all other individuals with the planning and delivering the content disclosed no relevant financial relationships.
    General Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.
    Commercial Support
    This is a program of the AGA in collaboration with RMEI, LLC. RMEI gratefully acknowledges an educational grant from Takeda Pharmaceuticals North America, Inc. in support of this CME activity.
    Fee Information
    There is no fee for this educational activity.
    Supported Browsers
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 18.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 13.0+ for Windows, Mac OS, or Linux
    Safari 4.0+ for Mac OSX 10.5 and above

    Supported Phones/Tablets
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above